Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Sirolimus

3 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBMT1760

    03/15/2018

    A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3)

    Treatment

    VICCNCPED1414

    04/24/2014

    HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

    Treatment

    VICCNCBMT12108

    05/08/2013

    A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies


    Print this page for your doctor